Overview

The primary objective of this study is to assess median progression free survival (PFS) using Response Assessment in Neuro-Oncology (RANO) Criteria following daily administration of PAX-1 as a treatment for newly diagnosed or recurrent GBM in combination with Investigator’s choice of standard of care (SOC).
For further information about this trial, please visit the Australia and New Zealand Clinical Trials Registry (ANZCTR).

FDA USA Listing correct as of 19/12/2019

Overview

This is a 2-part Phase 1 trial of PAX-1 in patients with metastatic solid tumors: Part 1 is dose escalation trial to determine Recommended Phase 2 Dose (RP2D) and Part 2 will evaluate the effect of food on the pharmacokinetics of PAX 1.